Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maher Hanoun

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Haematologica|June 16, 2022
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
British Journal of Cancer|August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Trials|November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Blood Cancer Journal|January 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcomeJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Haematologica|April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimensDavid Baden, Sven Zukunft, Gema Hernandez, et al.
Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Blood|March 13, 2026
IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple MyelomaJohanna M Horns, Thomas Beder, Axel Künstner, et al.
Annals of Hematology|July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLLydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Haematologica|June 16, 2022
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
British Journal of Cancer|August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Trials|November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Blood Cancer Journal|January 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcomeJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Haematologica|April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimensDavid Baden, Sven Zukunft, Gema Hernandez, et al.
Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Blood|March 13, 2026
IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple MyelomaJohanna M Horns, Thomas Beder, Axel Künstner, et al.
Annals of Hematology|July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLLydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.
Pageof 6